Enliven Therapeutics stockholders elect three Class II directors, ratify Deloitte as auditor at 2025 annual meeting

Enliven Therapeutics, Inc.

Elected Class II directors: Rahul D. Ballal (36,870,420 for), Jake Bauer (37,250,826 for), Andrew Phillips (31,957,928 for).
Ratified Deloitte & Touche LLP as independent auditor for FY2025 (45,392,647 for, 2,435 against, 35,215 abstain).
Broker non-votes of 8,099,804 existed for director elections; ratification had no broker non-votes.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.